Dere Willard H — SEC Form 4 filings
SEC reporting owner CIK 1311569. 12 Form 4 filings on record with FilingPulse; latest filed 2026-07-10.
Transaction summary — filings shown
Covers all 12 filings on record, filed 2024-04-03 to 2026-07-10. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Mersana Therapeutics, Inc. (MRSN) | Director | 3 | — | — | 15 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | Director | 3 | — | — | 3 |
| Metagenomi Therapeutics, Inc. (MGX) | Director | 3 | — | — | 3 |
| Seres Therapeutics, Inc. (MCRB) | Director | 3 | — | — | 3 |
Form 4 filings — Dere Willard H
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-10 | 4 | Seres Therapeutics, Inc. (MCRB) | Grant/award (A): 6,500 (derivative) @ $0 | EDGAR |
| 2026-06-11 | 4 | Metagenomi Therapeutics, Inc. (MGX) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 7,490 @ $0 | EDGAR |
| 2026-01-06 | 4 | Mersana Therapeutics, Inc. (MRSN) | Code (U): 1,567 · Disposition to issuer (D): 2,460 (derivative) · Disposition to issuer (D): 800 (derivative) · Disposition to issuer (D): 544 (derivative) · Disposition to issuer (D): 1,000 (derivative) · Disposition to issuer (D): 450 (derivative) · +7 more | EDGAR |
| 2025-06-13 | 4 | Mersana Therapeutics, Inc. (MRSN) | Grant/award (A): 61,500 (derivative) @ $0 | EDGAR |
| 2025-06-12 | 4 | Metagenomi, Inc. (MGX) | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2025-05-22 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 6,650 @ $0 | EDGAR |
| 2025-04-11 | 4 | Seres Therapeutics, Inc. (MCRB) | Grant/award (A): 100,000 (derivative) @ $0 | EDGAR |
| 2024-06-12 | 4 | Mersana Therapeutics, Inc. (MRSN) | Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2024-05-23 | 4 | BIOMARIN PHARMACEUTICAL INC (BMRN) | Grant/award (A): 4,720 @ $0 | EDGAR |
| 2024-04-08 | 4 | Seres Therapeutics, Inc. (MCRB) | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | Metagenomi, Inc. (MGX) | Grant/award (A): 78,636 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1311569 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →